prostate cancer

Showing 15 posts of 85 posts found.

Two-decade-long prostate cancer study finds antiandrogen improves survival

February 2, 2017
Research and Development antiandrogen, oncology, prostate cancer

Research conducted over the course of two decades has found a positive correlation between overall survival in prostate cancer patients …


“Biggest leap in decades” for prostate cancer, 1 in 4 could avoid biopsies

January 20, 2017
Medical Communications, Research and Development Biposy, prostate cancer

A new study has estimated that one in four men could avoid unnecessary invasive biopsies to detect prostate cancer – …


Scottish Medicines Consortium approves Sanofi’s prostate cancer drug

December 12, 2016
Manufacturing and Production, Sales and Marketing Jevtana, Sanofi, prostate cancer

Sanofi’s speciality care global business unit Sanofi Genzyme has announced that the Scottish Medicines Consortium has accepted the company’s Jevtana …

NICE recommends Bayer’s Xofigo for prostate cancer treatment

September 2, 2016
Medical Communications, Sales and Marketing Bayer, NICE, approval, prostate cancer, recommendation, xofigo

NICE has issued final draft guidance recommending Bayer’s Xofigo (radium-223 dichloride) for the treatment of prostate cancer. Previously, the drug …


Failure in pivotal Phase III study obliterates stock at Tokai Pharmaceuticals

July 27, 2016
Research and Development phase III, prostate cancer, tokai pharmaceuticals

Shares at Tokai Pharmaceuticals have been sent into freefall following the suspension of a pivotal Phase III trial for their …

Bayer, Orion to start Phase III trials for prostate cancer drug

June 3, 2016
Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research

German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase …

NICE recommends Jevtana for advanced prostate cancer

May 25, 2016
Sales and Marketing Jevtana, NICE, approval, prostate cancer, recommendation

The National Institute for Health and Care Excellence (NICE) has recommended Sanofi Genzyme’s Jevtana (cabazitaxel), in combination with prednisone or …


Phase III trial initiated for enzalutamide in treatment of prostate cancer

March 24, 2016
Research and Development Astellas, Medivation, arches, clinical trial, enzalutamide, phase 3, phase III, prostate cancer

Astellas Pharma (TSE: 4503) and Medivation (NASDAQ:MDVN) have announced the initiation of the ARCHES Phase III clinical trial to evaluate …


NICE approves Janssen’s Zytiga for prostate cancer before chemo

March 21, 2016
Sales and Marketing Janssen, NICE, Zytiga, prostate cancer

The National Institute for Health and Care Excellence (NICE) has recommended the use of Janssen’s Zytiga (abiraterone acetate) to treat …


Janssen’s Zytiga boosts survival in early-stage prostate cancer

March 14, 2016
Research and Development, Sales and Marketing Janssen, Zytiga, abiraterone, prednisone, prostate cancer

Janssen has announced data from a post-hoc analysis of a Phase III trial showing that Zytiga plus prednisone boosted overall …


AZ’s Lynparza gets prostate cancer breakthrough status

January 28, 2016
Sales and Marketing AstraZeneca, Breakthrough Therapy Designation, FDA, lynparza, olaparib, prostate cancer

AstraZeneca’s Lynparza has been granted breakthrough therapy designation by the FDA as a monotherapy for the treatment of a specific …

Exercise prostate cancer

Trial launched to test exercise as prostate cancer treatment

January 6, 2016
Research and Development Cancer Research UK, active surveillance, exercise, prostate cancer

Cancer Research UK has launched a study to determine if exercise could help men with prostate cancer, the UK’s most …

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015
Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …


NICE decision restricts Bayer’s Xofigo to select prostate cancer patients

November 19, 2015
Research and Development, Sales and Marketing Bayer, NICE, prostate cancer

NICE has issued its Final Appraisal Determination (FAD) recommending Bayer’s Xofigo (radium-223 dichloride) for use on the NHS in England …


New cancer medicines approved in Scotland, available via NHS

October 12, 2015
Sales and Marketing Scottish Medicines Consortium, Zytiga, abiraterone acetate, prostate cancer

The Scottish Medicines Consortium (SMC) has today recommended Janssen’s Zytiga (abiraterone acetate) for use before chemotherapy in men with advanced …

Latest content